Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Delbeck, V. Li, F. Von Nussbaum, D. Meibom, S. Golz, K. Lustig, H. Truebel, S. Schaefer (Wuppertal, Germany). Prevention of monocrotaline-induced pulmonary vascular and myocardial remodeling by the selective neutrophil elastase inhibitor BAY 85-8501. Eur Respir J 2014; 44: Suppl. 58, 2352

Member's Comments

No comment yet.

Related content which might interest you: Selective inhibition of neutrophil elastase by BAY 85-8501 improves exercise capacity and pulmonary hypertension in a porcine pancreatic elastase-induced emphysema model Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Role of NMDA receptors in vascular remodelling associated to pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Nebivolol and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Smooth muscle microparticles as novel biomarkers of vascular remodelling and inflammation in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Th17 inflammation and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Phosphodiesterase inhibitors as promising therapies for cigarette smoke-induced emphysema and pulmonary hypertension (PH) in mice Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Nuclear factor-kappa B inhibition exerts anti-remodelling effects in pulmonary arterial smooth muscle cells Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Female pulmonary arterial hypertension is associated with decreased microRNA96 expression Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 mir-126 contribute to angiogenesis defect in pulmonary arterial hypertension right ventricle failure Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Cerebral tissue oxygenation in arterial and thromboembolic pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Endothelial microparticles and progenitor cells in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Hemodynamic effects of different vasodilators in patients with type II pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 ASK1 promotes maladaptive remodeling in a rodent model of pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Intact serotonin signaling is not required for the development of severe angioproliferative pulmonary hypertension in rats Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Endothelial-to-mesenchymal transition in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014